Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.

Registrati

JNJ Johnson and Johnson

161,90

-1,81 (-1,11%)

01 Apr 2025 - Chiuso

Dati in Delay di 15 minuti

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212414962/en/

Media contact: media-relations@its.jnj.com

Investor contact: investor-relations@its.jnj.com

Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Mar 2025 a Apr 2025

Clicca qui per i Grafici di Johnson and Johnson

Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Apr 2024 a Apr 2025

Clicca qui per i Grafici di Johnson and Johnson

Notizie Johnson and Johnson - JNJ

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
Martedì 1 Aprile 2025 (5 ore fa) • Business Wire

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Mercoledì 26 Marzo 2025 (6 giorni fa) • PR Newswire (US)

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
Mercoledì 26 Marzo 2025 (6 giorni fa) • PR Newswire (US)

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
Venerdì 21 Marzo 2025 (2 settimane fa) • Business Wire

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
Giovedì 20 Marzo 2025 (2 settimane fa) • PR Newswire (US)

Form PX14A6G - Notice of exempt solicitation submitted by non-management
Giovedì 20 Marzo 2025 (2 settimane fa) • Edgar (US Regulatory)

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Giovedì 20 Marzo 2025 (2 settimane fa) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Giovedì 20 Marzo 2025 (2 settimane fa) • Edgar (US Regulatory)

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
Martedì 18 Marzo 2025 (2 settimane fa) • PR Newswire (US)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mercoledì 12 Marzo 2025 (3 settimane fa) • Edgar (US Regulatory)

Form ARS - Annual Report to Security Holders
Mercoledì 12 Marzo 2025 (3 settimane fa) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Mercoledì 12 Marzo 2025 (3 settimane fa) • Edgar (US Regulatory)

Più Johnson and Johnson Articoli Notizie

Delayed Upgrade Clock

Assistenza: support@advfn.it

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni